Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.

The Journal of clinical endocrinology and metabolism - 1 Mar 2014

O'Reilly Michael W, Taylor Angela E, Crabtree Nicola J, Hughes Beverly A, Capper Farfia, Crowley Rachel K, Stewart Paul M, Tomlinson Jeremy W, Arlt Wiebke

Abstract excerpt

CONTEXT: Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgens
Share to Androstenedione
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Hyperandrogenism

Share to Polycystic Ovary Syndrome

Share to Predictive Value of Tests

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 24423344
DOI: 10.1210/jc.2013-3399
PMCID: PMC3955250

Genes

SHBG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24423344-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.PMID 24423344Read ↗

High salivary testosterone-to-androstenedione ratio and adverse metabolic phenotypes in women with polycystic ovary syndrome.Semantic proximity Read ↗

Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome.Semantic proximity Read ↗

Role of androgen ratios in the prediction of the metabolic phenotype in polycystic ovary syndrome.Semantic proximity Read ↗

Can the source of hyperandrogenism in adolescents with polycystic ovary syndrome predict metabolic phenotype?Semantic proximity Read ↗

Androgen excess: a hallmark of polycystic ovary syndrome.Semantic proximity Read ↗

Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary SyndromeSemantic proximity Read ↗

Defining Hyperandrogenism in Women With Polycystic Ovary Syndrome: A Challenging Perspective.Semantic proximity Read ↗

Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.Semantic proximity Read ↗

Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.Semantic proximity Read ↗

Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes.Semantic proximity Read ↗

Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups.Semantic proximity Read ↗

Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.